Effects of torcetrapib in patients at high risk for coronary events  by Barter, P.J. et al.
Abstracts
Gregory L. Moneta, MD, Abstracts Section EditorLong-term predictors of descending aorta aneurismal change in
patients with aorta dissections
Song J-N, Kim S-D, Kim J-H, et al. J Am Coll Card 2006;50:799-804.
Conclusion: Aneurysmal dilatation as a late manifestation of aortic
dissection is most likely to take place in the upper thoracic aorta. Aneurysmal
dilatation of the upper thoracic aorta is predicted by a large false lumen
diameter on the initial computed tomography (CT) scan.
Summary: After acute aortic dissection, late aneurysmal dilatation of
the aorta is a significant complication. The authors sought to demonstrate
the long-term natural history of descending aorta dilatation after acute aortic
dissection. They also sought to identify early predictors of late aneurysmal
change in the dissected aorta. Contrast-enhanced CT scans for acute aortic
dissection were performed in 100 patients. There were 51 patients with
DeBakey type 1 dissections and 49 patients with DeBakey type 3 dissections.
The patients with type 1 dissections underwent ascending aortic surgery
24 hours of diagnosis.
Clinical follow-up was for 53  26 months, and CT scans were
repeated at a mean of 31  27 months. Aortic dilatation to 60 mm
occurred in 14.4% of the upper thoracic descending aortas, 8.2% of the
middle descending thoracic aortas, 4.1% in the lower descending thoracic
aortas, and in 3.1% of the abdominal aortas. A repeat CT scan was done in 53
patients2 years after the initial dissection. On the basis of these scans, rates
of aortic enlargement per year at the upper, middle, and lower thoracic, and
abdominal aorta levels were 3.43  3.66, 3.21  2.70, 2.62  2.19, and
1.93  3.66 mm, respectively (P  .01). Aneurysms developed in 28%.
Predictors of late aneurysmal change included the initial false lumen diam-
eter of the upper thoracic aorta, aortic diameter in the middle thoracic aorta,
and Marfan syndrome. A22-mm initial false lumen diameter of the upper
thoracic aorta predicted late aneurysmal degeneration with a sensitivity of
100% and a specificity of 76%. The 42 patients with initial upper thoracic
aorta false lumen diameters22 mm also had a higher rate of the combina-
tion of aneurysm formation and death (P  .001).
Comment: The study suggests patients with acute aortic dissection
with large false lumens of their upper thoracic aorta may be ones where
prophylactic stent grafting might be beneficial. A European trial that has
either just begun, or will begin soon, is investigating the impact of stent
grafting on uncomplicated acute type 3 aortic dissections, the ADSORB
(Acute Dissection Stenting or BestMedical Treatment study). Results of this
trial will, hopefully, help determine the optimal role of stent grafting for
acute aortic dissection.
Early results after staged hybrid repair of thoracoabdominal aortic
aneurysms
Lee WA, Brown MP, Martin TD, Seeger JM, et al. J Am Coll Surg
2007;2005:420-31.
Conclusion: The hybrid approach of thoracoabdominal aneurysm
(TAA) repair can be performed with relatively few technical complications,
but morbidity and mortality rates remain significant.
Summary: The authors reviewed the morbidity and mortality associ-
ated with the hybrid approach of TAA repair. This is a retrospective review of
17 patients (mean age, 69 15 years, 76% men), who underwent renal and
visceral revascularization as a first stage of a hybrid repair of a TAA. The
TAAs treated in this study included two Crawford extent type II, eight type
III, and seven type IV. Perioperative mortality and complication rates
associated with the debranching portion of the procedure were 24% and
25%, respectively. The mean intensive care unit stay and hospital stay were 7
12 days and 22 33 days, respectively. The mean delay between the staged
procedures was 27  27 days. The thoracic stent graft (stage 2) was placed
in 12 (92%) of the 13 patients who survived the initial portion of the
procedure. No additional deaths or postoperative complications were asso-
ciated with the second stage of the procedure. After the second stage,
patients did not require intensive care unit stay, and the overall length of stay
after the procedure was 2  2 days. Postoperative follow-up among 11
patients completing both stages was 8  12 months, with no additional
deaths during follow-up. Primary patency for renal and visceral grafts was
96% (54 of 56).
Comment:The hybrid approach to TAA repair is difficult operation for
both the patient and the surgeon. If complete debranching of the aorta is
performed, and a conduit is placed for subsequent placing of the thoracic
endograft, operative times of 6 to 9 hours are expected. Mortality and
morbidity rates are significant. The hybrid approach to TAA repair, although
a tribute to surgical technical expertise, is not likely to be the final word in the
surgical treatment of patients with TAAs. We await the availability of anoff-the-shelf branched stent graft that can be implanted with a reasonable
and not exceptional level of technical expertise.
Effects of torcetrapib in patients at high risk for coronary events
Barter PJ, Caulfield M, Eriksson M, and the ILLUMINATE Investigators.
N Engl J Med 2007;357:2109-22.
Conclusion: Torcetrapib therapy, which increases high-density li-
poprotein (HDL), results in an increased risk of mortality and morbidity.
Summary: Cholesteryl ester transfer protein (CETP) results in
transfer of cholesteryl esters from HDL to other lipoproteins. Inhibiting
CETP therefore results in increased HDL cholesterol levels and results in
decreased low-density lipoprotein (LDL) cholesterol levels. Given these
possible antiatherogenic effects, it would seem reasonable that torce-
trapib, an inhibitor of CETP, would have a favorable effect on morbidity
and mortality. To test this hypothesis, the authors conducted a double-
blind randomized study of 15,067 patients considered at high cardiovas-
cular risk. Patients were treated with atorvastatin alone or torcetrapib
plus atorvastatin. The primary outcome was time to the first major
cardiovascular event, which was defined as death from coronary heart
disease, stroke, or hospitalization for unstable angina or nonfatal myo-
cardial infarction.
In patients receiving torcetrapib therapy, after 12 months, there was an
increase of 72.1% in HDL and a decrease of 24.9% in LDL cholesterol
compared with baseline (P .001), and there was also an increase in systolic
blood pressure of 5.4 mmHg. Serum sodium, bicarbonate, and aldosterone
levels all also increased in patients treated with torcetrapib (P  .001).
Patients treated with torcetrapib had an increased risk of cardiovascular
events (hazard ratio, 1.25; 95% confidence interval, 1.09-1.44; P .001) as
well as an increase of death from any cause (hazard ratio 1.58; 95% confi-
dence interval, 1.14-2.19; P  .006). Post hoc analysis indicated there was
an increased risk of death in patients with torcetrapib therapy who had
increases in bicarbonate or reductions in potassium levels greater than the
median change.
Comment: This study documented a number of off-target pharmaco-
logic effects of torcetrapib. The increase of systolic blood pressure, as well as
the metabolic effects, may have negated the effects of improvement in HDL
and LDL levels induced by torcetrapib. This study, therefore, neither
validates nor invalidates the possibility that raising HDL cholesterol
levels by inhibition of CETP can be cardio productive. As the authors
point out in the discussion of the article, this hypothesis can only be
tested by use of a CETP inhibitor that does not share the off-target
pharmacologic effects of torcetrapib.
Childhood body-mass index and the risk of coronary heart disease in
adulthood
Baker JL, Olsen LW, Sorensen TIA. N Engl J Med 2007;357:2329-37.
Conclusion: Increases in the bodymass index (BMI) during childhood
are associated with an increased risk of coronary heart disease (CHD) in
adulthood.
Summary: Children are becoming overweight at progressively
younger ages, with 19% of children aged 6 to 11 years in the United States
considered overweight (Int J Obes Relat Metab Disord 2002;26[suppl 4]:S2-
S4, and JAMA 2006;295:1549-55). In this study, the authors sought to
determine long-term effects of increased weight in childhood CHD. Au-
thors studied the association between BMI in children aged 7 to 13 years and
CHD in adults aged 25 years. Data were analyzed with and without
adjustment for birth weight.
Subjects were derived from a cohort of 276,845 school children in
Denmark whose height and weight measurements were available. National
registries were used to determine CHD events. There were 5,063,622
person-years of follow-up. A total of 10,235 adult men and 4318 adult
women had a diagnosis of CHD or died of CHD for whom childhood BMI
data were also available. Risk of fatal and nonfatal events and any CHD event
in the adults were positively associated with BMI from 7 to 13 years of age
for boys and from 10 to 13 years of age for girls. Risk increased across the
entire BMI distribution, and associations were linear for each age. Risk also
increased as the age of the child increased. Adjustment for birth weight
strengthened the results.
Comment: The data provide some quantitative information on the
adverse effect of childhood obesity on future health. The magnitude of
increased risk of CHD is relatively modestly increased in children at 7 years
of age and dramatically increases further by age 13. Parents must somehow
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